Literature DB >> 1739616

Type III collagen metabolism in soft tissue sarcomas.

T A Wiklund1, I Elomaa, C P Blomqvist, L Risteli, J Risteli.   

Abstract

Sera of 85 patients with benign soft tissue lesions or sarcomas of soft tissues were investigated for a collagen metabolite, the aminoterminal propeptide of type III procollagen (PIIINP). Patients were divided into three groups: benign soft tissue lesions (n = 39), localised (n = 29) and metastatic (n = 18) soft tissue sarcomas (STS). Values of PIIINP above the reference range were found in 15%, 28% and 50% of the respective groups. The difference in the concentration of PIIINP was statistically significant between the benign lesions and the localised sarcomas; P = 0.05, and between the benign lesions and the metastatic sarcomas; P less than 0.001. In localised sarcomas there was a correlation between PIIINP and bone-involvement (r = 0.61, P = 0.002) and in metastatic disease between PIIINP and liver metastases (r = 0.77, P less than 0.001). In localised sarcomas the overall survival for patients with a value of PIIINP above the reference range was significantly poorer (P = 0.03) than for patients with values within the reference range, even after stratification for the histological malignancy grade of the tumours (P = 0.04).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1739616      PMCID: PMC1977732          DOI: 10.1038/bjc.1992.40

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?

Authors:  L Risteli; A Kauppila; U M Mäkilä; J Risteli
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

2.  Collagen fibrillogenesis in human skin.

Authors:  R Fleischmajer; J S Perlish; R Timpl
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.

Authors:  C Tomás; J Penttinen; J Risteli; L Risteli; J Vuori; A Kauppila
Journal:  Cancer       Date:  1990-12-01       Impact factor: 6.860

4.  The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism.

Authors:  C Blomqvist; I Elomaa; P Virkkunen; L Porkka; S L Karonen; L Risteli; J Risteli
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

5.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.

Authors:  J Risteli; S Niemi; P Trivedi; O Mäentausta; A P Mowat; L Risteli
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

6.  Collagen metabolism in normal and complicated pregnancy: changes in the aminoterminal propeptide of type III procollagen in serum.

Authors:  L Risteli; U Puistola; H Hohtari; A Kauppila; J Risteli
Journal:  Eur J Clin Invest       Date:  1987-02       Impact factor: 4.686

7.  Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis.

Authors:  J Risteli; H Søgaard; A Oikarinen; L Risteli; J Karvonen; H Zachariae
Journal:  Br J Dermatol       Date:  1988-09       Impact factor: 9.302

8.  Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.

Authors:  K Haukipuro; L Risteli; M I Kairaluoma; J Risteli
Journal:  Surgery       Date:  1990-04       Impact factor: 3.982

9.  Aminoterminal propeptide of type III procollagen is cleared from the circulation by receptor-mediated endocytosis in liver endothelial cells.

Authors:  B Smedsrød
Journal:  Coll Relat Res       Date:  1988-07

10.  Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.

Authors:  C Tomás; J Penttinen; J Risteli; L Risteli; A Kauppila
Journal:  Ann Med       Date:  1990-04       Impact factor: 4.709

View more
  4 in total

1.  Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.

Authors:  T A Wiklund; C P Blomqvist; L Risteli; J Risteli; I Elomaa
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Type I and type III collagen metabolites in adult osteosarcoma patients.

Authors:  T Wiklund; C Blomqvist; L Risteli; J Risteli; E Karaharju; I Elomaa
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

3.  Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

Authors:  C Blomqvist; L Risteli; J Risteli; P Virkkunen; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

4.  Serum levels of laminin, type IV collagen and type III procollagen peptide as markers for detection of metastasis.

Authors:  K Yudoh; H Matsui; M Kanamori; K Ohmori; H Tsuji; S Tatezaki
Journal:  Jpn J Cancer Res       Date:  1994-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.